Impact of galectin 3 as myofibrosis marker in clinical cardiology

Česká verzia

Authors: Filip Málek
Authors place of work: Kardiovaskulární centrum Nemocnice Na Homolce Praha, přednosta prim. MUDr. Ivo Skalský, MBA
Published in the journal: Vnitř Lék 2014; 60(4): 327-330
Category: 60th Birthday - prof. MUDr. Petr Widimský, DrSc., FESC, FACC

Summary

Galectin 3 is a protein secreted by activated macrophages and has a role in development of fibrosis in injured tissues. Experimental studies showed increased galectin 3 secretion in the context of cardiac hypertrophy and heart failure models. Several clinical studies identified galectin 3 to be a biomarker of cardiovascular diseases in the field of diagnosis, risk stratification, monitoring therapy response and predicting short-term and long-term prognosis. Particularly, the additional prognostic information of galectin 3 as assessed together with NT-proBNP was established in acute and chronic heart failure.

Key words:
galectin 3 – heart failure – myofibrosis – outcome prediction

Zdroje

1. Braumwald E. Biomarkers in heart failure. New Engl J Med 2008; 358(20): 2148–2159.

2. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res 1999; 41(3): 532–543.

3. Málek F. Arteriální hypertenze a chronické srdeční selhání. Cor et Vasa 2013; 55(3): 325–329.

4. Weber KT, Brilla CG. Pathological hypertrophy and cardiac inter- expression and NADPH oxidase activity are increased in aortas from stitium. Fibrosis and renin-angiotensin-aldosterone system. Circu-hypertensive rats. Circulation 1991; 83(6): 1849–1865.

5. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 2008; 10: E17. Dostupné z DOI: <http:// doi: 10.1017/S1462399408000719>.

6. Barboni EA, Bawumia S, Henrick K et al. Molecular modeling and mutagenesis studies of the N-terminal domains of galectin-3: evidence for participation with the C- terminal carbohydrate recognition domain in oligosaccharide binding. Glycobiology 2000; 10(11): 1201–1208.

7. Kramer F. Galectin-3: clinical utility and prognostic value in patients with heart failure. Res Reports Clin Cardiol 2013; 4: 13–22.

8. Nieminen J, St-Pierre C, Bhaumik P et al. Role of galetin-3 in leukocyte recruitement in a murine model of lung infection by Streptococcus pneumoniae. J Immunol 2008; 180(4): 2466–2473.

9. Gupta SK, Masinick S, Garrett M et al. Pseudomonas aeruginosa lipopolysacharide binds galectin-3 and other human corneal epithelial proteins. Infect Immun 1997; 65(7): 2747–2753.

10. Sharma UC, Pokharel S, van Brakel TJ et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110(19): 3121–3128.

11. Schroen B, Heymans S, Sharma U et al. Thrombospondin-2 is Essentials for myocardial matrix integrity: increased expression identifies silure-prone cardiac hypertrophy. Circ Res 2004; 95(5): 515–522.

12. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in Cardiac Remodeling and Heart Failure. Curr Heart Fail Rep 2010; 7(1): 1–8.

13. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006; 103(13): 5060–5065.

14. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue Indry. J Biol Chem 2000; 275(4): 2247–2250.

15. Henderson NC, Mackkinnon AC, Farnworth SL et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008; 172(2): 288–298.

16. Nishi Y, Sano H, Kawashima T et al. Role of galectin-3 in human pulmonary fibrosis. Allergol Int 2007; 56(1): 57–65.

17. Wang L, Friess H, Zhu Z et al. Galectin-1 and galectin-3 in chronic pancreatitis. Lab Invest 2000; 80(8): 1233–1241.

18. de Boer RA, Voors AA, Muntendam P et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009; 11(9): 811–817.

19. van Kimmenade RR, Januzzi jr. JL, Ellinor PT et al. Utility of aminoterminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Col Cardiol 2006; 48(6): 1217–1224.

20. Kjekshus J, Apetrei E, Barrios V et al (for the CORONA Group). Rosuvastatin in Older Patients with Systolic Heart Failure. N Engl J Med 2007; 357(22): 2248–2261.

21. Cleland JGF, Daubert JC, Erdmann E et al. the Cardiac Resynchronization- Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352(15): 1539–1549.

22. Gullestad L, Ueland T, Kjekshus J et al. CORONA Study Group Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J 2012; 33(18): 2290–2296.

23. Lopez-Andrès N, Rossignol P, Iraqi W et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012; 14(1): 74–81.

24. Januzzi jr. JL, Camargo CA, Anwaruddin S et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95(8): 948–954.

25. Jaarsma T, van der Wal MHL, Lesman-Leegte I et al (for the coordinating study evaluating outcomes of advising and counseling in heart failure – COACH). Effect of moderate or intensive disease management on outcome in patients with heart failure. Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Int Med 2008; 168(3): 316–324.

26. Lok DJ, Van Der Meer P, de la Porte PW et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from DEAL-HF study. Clin Res Cardiol 2010; 99(5): 323–328.

27. Lok DJ, van der Meer P, de La Porte PB et al. Galectin-3, a Novel Marker of Macrophage Activity, Predicts Outcome in Patients With Stable Chronic Heart Failure. J Am Coll Cardiol 2007; 49(9 Suppl 1): 98A.

28. de Boer RA, Lok DJ, Jaarsma T et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43(1): 60–68.

29. de Boer RA, va Veldhuisen DJ, Gansevoort RT et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012; 272(1): 55–64.

30. Ho JE, Liu Ch, Lyass A et al. Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community. J Am Coll Cardiol 2012; 60(14): 1249–1256.